Special Issue on “5-Fluorouracil

(http://www.mdpi.org/molecules/specialissues/fluorouracil.htm)

Dear Colleagues,
 
We would like to invite you to contribute a paper for publication in the Special Issue
5-Fluorouracil”of Molecules (http://www.mdpi.org/molecules).
Both comprehensive review articles and full research papers are invited.

For nearly 50 years the molecule 5-fluorouracil (5-FU) has been the main cytotoxic
agent for treatment of colorectal cancer. We would like to provide a venue for exhaustive
discussion on all aspects about this molecule.

This thematic special issue will be fully Open Access with publishing fees paid by authors.
Open Access (unlimited access by readers) increases publicity and promotes more
frequent citations as indicated by several studies. More information is available
at http://www.mdpi.org/oaj-supports.htm.

You may send your manuscript soon or by 15 June 2008 (Postponed to 15 October 2008). Papers accepted will
be published immediately. Finally, all the papers belonging to this special issue
will be gathered together in a homepage. Therefore, you may submit your paper
now. The time taken between submission and publication is less than 1 month now.

For review papers, the title and a short abstract can be sent to [email protected]
(copy to Dr. Francesco Puoci, E-mail: [email protected]) as soon as possible
so that we can consider its suitability.

Molecules (http://www.mdpi.org/molecules) maintains a
rigorous and fast peer-review system. Accepted papers
are immediately published online. Well written papers have been peer reviewed
and published in less than two weeks from manuscript submission, see the example:
http://www.mdpi.org/molecules/papers/11040212.pdf.

Please send your paper by e-mail to [email protected] with a copy to me
at E-mail: [email protected]. The subject title of the
message should be "Manuscript for Special Issue "5-Fluorouracil".

You may send your abstracts to me first. We will list them at
http://www.mdpi.org/molecules/specialissues/fluorouracil.htm.

Looking forward to hearing from you.

Dr. Francesco Puoci
E-mail: [email protected]